PBTC33: A Phase I /II Study of ABT-888, an Oral Poly (ADP-Ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide (TMZ), in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)


Brain Tumor : newly diagnosed diffuse intrinsic pontine gliomas (DIPG)


Diffuse Intrinsic pontine gliomas are located in the brainstem, at the base of the brain. They are usually diagnosed in children aged 5 to 10 years. They are difficult to treat because the tumor cells grow in between and around normal cells. These tumors are generally treated with radiation therapy, which is a combination of high-energy X-rays that destroy tumor cells. This treatment can reduce symptoms significantly, but even with radiation therapy, the cure rate is still very low for these tumors. New drugs such as ABT-888 are being investigated to assist with the search for treatments that can improve survival in these patients.

The phase I portion of this study will help to find out the highest safe dose of ABT-888 that can be given with radiation therapy to treat children with DIPG. While doctors know the safe dose of ABT-888 and TMZ when given together, they do not yet know the safe dose of ABT-888 when it is given at the same time as radiation treatment. The phase II portion of this study will help to find out the efficacy of this treatment in patients with DIPG.




Ibrahim Qaddoumi MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2544 or 901-595-4599
FAX: 901-595-5353


Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544

For the current eligibility status of this clinical study, patient’s family, relatives and/or referring physicians may contact St. Jude Children’s Research Hospital at (901) 595-4599 or (901) 595-2544.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.